E. Gérard

666 total citations
38 papers, 216 citations indexed

About

E. Gérard is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, E. Gérard has authored 38 papers receiving a total of 216 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 12 papers in Molecular Biology and 11 papers in Epidemiology. Recurrent topics in E. Gérard's work include Cancer Immunotherapy and Biomarkers (17 papers), Cutaneous Melanoma Detection and Management (10 papers) and Melanoma and MAPK Pathways (9 papers). E. Gérard is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Cutaneous Melanoma Detection and Management (10 papers) and Melanoma and MAPK Pathways (9 papers). E. Gérard collaborates with scholars based in France, United States and Belgium. E. Gérard's co-authors include S. Prey, Caroline Dutriaux, M. Beylot‐Barry, Anne Pham‐Ledard, L. Dousset, RK Shadduck, G. Chikkappa, O. Cogrel, A.L. Carsten and M.‐S. Doutre and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and British Journal of Cancer.

In The Last Decade

E. Gérard

29 papers receiving 211 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Gérard France	10	129	56	47	32	28	38	216
Georgios L. Moschovakis Germany	6	91 0.7×	206 3.7×	37 0.8×	25 0.8×	20 0.7×	6	322
Max Bittrich Germany	9	130 1.0×	57 1.0×	101 2.1×	13 0.4×	39 1.4×	20	243
Bella Shadur Australia	10	39 0.3×	97 1.7×	65 1.4×	35 1.1×	11 0.4×	20	214
Haruhisa Machida Japan	8	63 0.5×	85 1.5×	47 1.0×	34 1.1×	47 1.7×	11	233
Julie Ducreux Belgium	9	46 0.4×	121 2.2×	72 1.5×	16 0.5×	17 0.6×	14	267
Branka Petričević Austria	7	147 1.1×	166 3.0×	76 1.6×	29 0.9×	40 1.4×	13	298
Armin Rabsteyn Germany	6	45 0.3×	110 2.0×	50 1.1×	11 0.3×	16 0.6×	13	179
Adeeb NaserEddin Israel	10	59 0.5×	144 2.6×	85 1.8×	47 1.5×	14 0.5×	20	279
Jichang Han China	6	167 1.3×	178 3.2×	60 1.3×	15 0.5×	37 1.3×	13	299
David M. Ellison United States	5	51 0.4×	61 1.1×	71 1.5×	21 0.7×	18 0.6×	7	173

Countries citing papers authored by E. Gérard

Since Specialization

Citations

This map shows the geographic impact of E. Gérard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Gérard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Gérard more than expected).

Fields of papers citing papers by E. Gérard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Gérard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Gérard. The network helps show where E. Gérard may publish in the future.

Co-authorship network of co-authors of E. Gérard

This figure shows the co-authorship network connecting the top 25 collaborators of E. Gérard. A scholar is included among the top collaborators of E. Gérard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Gérard. E. Gérard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schneider, S., E. Gérard, Caroline Dutriaux, et al.. (2025). Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors. European Journal of Cancer. 217. 115223–115223. 1 indexed citations

Nardin, Charlée, Célèste Lebbé, Cécile Pagès, et al.. (2024). Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).. Journal of Clinical Oncology. 42(16_suppl). 9578–9578.

Schneider, S., L. Dousset, S. Prey, et al.. (2024). Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas. Journal of Cancer Research and Clinical Oncology. 150(3). 133–133. 1 indexed citations

Barnetche, Thomas, S. Prey, Caroline Dutriaux, et al.. (2024). Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study. Joint Bone Spine. 92(1). 105795–105795. 1 indexed citations

Duval, Fanny, et al.. (2023). Case report: Parsonage-turner syndrome in a melanoma patient treated by BRAF/MEK inhibitors after immune checkpoint inhibitors. Frontiers in Oncology. 13. 1268693–1268693.

Gérard, E., Célèste Lebbé, Émilie Lanoy, et al.. (2023). 1140P Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA. Annals of Oncology. 34. S683–S683. 3 indexed citations

Prey, S., Caroline Dutriaux, E. Gérard, et al.. (2023). Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors. European Journal of Cancer. 197. 113477–113477. 3 indexed citations

Nardin, Charlée, Elisa Funck‐Brentano, Valentine Heidelberger, et al.. (2023). Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers. 15(14). 3564–3564. 12 indexed citations

Pham‐Ledard, Anne, E. Gérard, Caroline Dutriaux, et al.. (2023). Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases. Journal of Immunotherapy. 46(7). 276–278. 1 indexed citations

10.

Adam, Julien, Laurence Lamant, Maxime Battistella, et al.. (2022). Harmonization of programmed death‐ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis. Histopathology. 80(7). 1091–1101. 6 indexed citations

11.

Allain, Nathalie, Mélanie Moreau, Arnaud Jabouille, et al.. (2022). Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. Oncogene. 41(18). 2571–2586. 17 indexed citations

12.

Gérard, E., O. Cogrel, Anne Pham‐Ledard, et al.. (2022). Clinical features associated with the invasive component in lentigo maligna of the head and neck: A retrospective study of 175 cases. Annales de Dermatologie et de Vénéréologie. 149(4). 258–263. 2 indexed citations

13.

Dousset, L., S. Prey, Caroline Dutriaux, et al.. (2021). Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study. Journal of Oncology. 2021. 1–8. 15 indexed citations

14.

Dousset, L., Thomas Barnetche, Marie Kostine, et al.. (2021). Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study. JAAD International. 5. 112–120. 15 indexed citations

15.

Dousset, L., C. Mertens, E. Gérard, et al.. (2020). Impact sur la qualité de vie et l’autonomie des patients de plus de 75 ans traités par anti-PD-1 pour un mélanome métastatique : étude prospective monocentrique. Annales de Dermatologie et de Vénéréologie. 147(11). 713–720. 1 indexed citations

16.

Dutriaux, Caroline, S. Prey, E. Gérard, et al.. (2020). Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma. Journal of Geriatric Oncology. 11(8). 1340–1343. 4 indexed citations

17.

Barnetche, Thomas, et al.. (2020). Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: A survey study. Journal of the American Academy of Dermatology. 83(4). 1188–1191. 3 indexed citations

18.

Dousset, L., et al.. (2019). Synergie de la séquence immunothérapie par anti-PD1 et radiothérapie au cours d’un carcinome basocellulaire avancé. Annales de Dermatologie et de Vénéréologie. 147(3). 228–232. 1 indexed citations

19.

Rousset, Marine, Caroline Dutriaux, Pauline Bosco‐Lévy, et al.. (2017). Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. Clinica Chimica Acta. 472. 26–29. 28 indexed citations

20.

Gérard, E., et al.. (2016). Risk factors, clinical variants and therapeutic outcome of retronychia: a retrospective study of 18 patients. European Journal of Dermatology. 26(4). 377–381. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact